← All Lantern Pharma INC filings

Lantern Pharma INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
LTRN
Lantern Pharma INC
10-K/A: Lantern Pharma Files Amendment to Annual Report
Lantern Pharma Inc. has filed an amendment to its 2025 Form 10-K, primarily to include previously omitted information regarding directors, executive officers, and corporate governance.
NASDAQ
LTRN
Lantern Pharma INC
10-K: Lantern Pharma Reports 2025 Losses, Seeks Funding Amid Clinical Progress
Lantern Pharma, an AI-driven oncology firm, reported continued net losses in 2025 and faces substantial doubt about its ability to continue as a going concern, despite advancing multiple drug candidates and expanding its AI platform.
NASDAQ
LTRN
Lantern Pharma INC
10-K/A: Lantern Pharma Files Amendment to 10-K, Updates Executive and Director Information
Lantern Pharma files an amendment to its 2024 Annual Report on Form 10-K to include previously omitted information regarding directors, executive officers, and corporate governance.
NASDAQ
LTRN
Lantern Pharma INC
10-K: Lantern Pharma Inc. Reports Annual Results for Fiscal Year 2024, Highlights AI-Driven Oncology Drug Development
Lantern Pharma Inc. outlines its progress in AI-driven oncology drug development and reports its financial results for the fiscal year ended December 31, 2024.
NASDAQ
LTRN
Lantern Pharma INC
10-K: Lantern Pharma Inc. 2023 Annual Report: AI-Driven Oncology Drug Development
Lantern Pharma's 2023 annual report highlights its focus on leveraging AI and genomic data to advance its oncology drug pipeline, including clinical trials for LP-300, LP-184, and LP-284.